

August 04, 2022

Corporate Relationship Department
BSE Limited,
PJ Towers, Dalal Street,
Mumbai- 400001

Dear Sirs

Sub: Outcome of the Board meeting- Unaudited Financial Results and Limited Review Report for the quarter ended June 30, 2022

**Ref: 1) Regulation 33 of SEBI (LODR) Regulations 2015
2) Script Code: 526783**

In terms of Regulation 30, 33 and other applicable provisions of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("LODR Regulations"), we wish to inform that the Board of Directors of the company at its meeting held today i.e., on August 04, 2022, commenced at 11.45 A.M and concluded at 1.40 P.M. have inter alia transacted the following businesses:


- 1) Approved the Un-Audited Financial Results of the Company for the quarter ended June 30, 2022. Copies of the Un-Audited Financial Results and Limited Review Report issued by the Statutory Auditors of the company for the said quarter is enclosed.
- 2) The Company has made arrangement for release of the Un-Audited Financial Results for the quarter ended June 30, 2022, in the newspaper as per the requirement of the LODR Regulations.

Kindly take the above information on record.

Thanking you,

Yours sincerely,

For **Dr. Agarwal's Eye Hospital Limited**



Meenaskhi Jayaraman
Company Secretary and Compliance Officer

Encl: a/a





Dr. Agarwal's Eye Hospital Limited
CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No. 4, Moores Road, Off Greaves Road, Chennai - 600 006
Phone No. 91-44-39915669 Website : www.dragarwal.com E-mail : investor@dragarwal.com
Statement of Unaudited Financial Results for the Quarter Ended 30 June 2022


(Amount Rs. in Crores except earnings per share data)

S.No.	Particulars	Quarter Ended		Year Ended	
		30-Jun-22	31-Mar-22	30-Jun-21	31-Mar-22
		Unaudited	(Refer Note 3)	Unaudited	Audited
1	Income				
	(a) Revenue from Operations	66.39	55.66	30.87	201.21
	(b) Other Income	0.20	0.26	0.32	1.26
	Total Income	66.59	55.92	31.19	202.47
2	Expenses				
	(a) Purchase of Stock-in-Trade	7.70	6.56	3.80	23.67
	(b) Changes in Inventories of Stock-in-Trade - (Increase) / Decrease	(0.52)	(0.21)	-	(0.81)
	(c) Surgical Lens including other consumables	7.66	6.36	3.25	23.78
	(d) Consultancy Charges	9.17	7.68	5.65	28.60
	(e) Employee Benefit Expenses	12.64	9.57	8.83	38.51
	(f) Finance Costs	2.18	1.73	1.44	6.23
	(g) Depreciation and Amortisation Expense	5.70	5.65	5.04	20.39
	(h) Other Expenses	9.95	9.36	4.16	29.79
	Total Expenses	54.48	46.70	32.17	170.16
3	Profit / (Loss) before Tax [1-2]	12.11	9.22	(0.98)	32.31
4	Tax Expense				
	- Current Tax	3.34	1.68	-	8.21
	- Deferred Tax	(0.34)	0.63	(0.25)	0.00
5	Net Profit / (Loss) after tax for the period [3-4]	9.11	6.86	(0.73)	24.10
6	Other Comprehensive Income				
	(a) Items that will not be reclassified to the Statement of Profit and Loss				
	- Actuarial (loss) / gain on defined benefit obligation	(0.22)	(0.79)	-	(0.79)
	- Tax on items that will not be reclassified to the Statement of Profit and Loss	0.06	0.20	-	0.20
	(b) Items that will be reclassified to the Statement of Profit and Loss	-	-	-	-
	Total Other Comprehensive Income / (Loss) (net of tax)	(0.16)	(0.59)	-	(0.59)
7	Total Comprehensive Income / (Loss) [6+7]	8.95	6.27	(0.73)	23.51
8	Paid-up equity share capital (Face value Rs.10/- each)	4.7	4.7	4.7	4.7
9	Reserves (Other Equity)				73.47
10	Earnings Per Equity Share (EPS) (Face value of Rs.10/- each)				
	(a) Basic	19.38	14.60	(1.56)	51.29
	(b) Diluted	19.38	14.60	(1.56)	51.29
		(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

Notes:

- The above unaudited financial results have been prepared in accordance with the Indian Accounting Standards ("Ind AS") notified under section 133 of the Companies Act, 2013, read together with the companies (Indian Accounting Standards) Rules, 2013 (as amended).
- The above unaudited financial results have been reviewed by the Audit Committee, approved and taken on record by the Board of Directors in their Meeting held on 4 August 2022. The above results for the quarter ended 30 June 2022 has also been subject to limited review by the Statutory Auditors of the Company.
- The figures for the quarter ended 31 March 2022 are the balance figures between the audited figures for the year ended 31 March 2022 and the unaudited year to date figures for the nine months ended 31 December 2021, which were subjected to limited review by the Statutory Auditors.
- The Company operates in a single segment i.e. "Eye Care related sales and services" and hence, does not have any additional disclosures to be made under Ind AS 108 - Operating Segments.
- The Company's operations for the quarter ended 30 June 2021 was impacted on account of the outbreak of COVID-19 pandemic. The results for the quarter are, therefore, not comparable with the corresponding previous period.
- The Code on Wages 2019 and Code on Social Security 2020 "the Codes" relating to employee compensation and post-employment benefits received the Presidential Assent in September 2020 and the Code has been published in the Official Gazette. However, the date on which the Code will come into effect has not been notified. The Company will assess the impact of the Code when it comes into effect and will record any related impact in the period when the Code becomes effective.

By order of the Board


Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684

Place : Chennai
Date : 04 August 2022





INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS

TO THE BOARD OF DIRECTORS OF DR. AGARWAL'S EYE HOSPITAL LIMITED

1. We have reviewed the accompanying Statement of Unaudited Financial Results of **DR. AGARWAL'S EYE HOSPITAL LIMITED** ("the Company"), for the quarter ended 30 June 2022 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India (ICAI). A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For **DELOITTE HASKINS & SELLS**
Chartered Accountants
(Firm's Registration No. 008072S)



Ananthi Amarnath
(Partner)
(Membership No. 209252)



Dr. Agarwal's Eye Hospital Limited
CIN : L85110TN1994PLC027366

Regd Office: 3rd Floor, Buhari Towers, No.4, Moores Road, Off Greaves Road, Chennai - 600 006
Phone No. 91-44-39916669 Website : www.dragarwal.com E-mail : investor@dragarwal.com

(Amount in Rs. Crores)

Statement of Unaudited Financial Results for the Quarter Ended 30 June 2022

Particulars	Quarter Ended 30 June 2022	Quarter Ended 31 March 2022	Quarter Ended 30 June 2021	For the Year Ended 31 March 2022 (Audited)
Revenue from Operations	66.39	55.66	30.87	201.21
Net Profit / (Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	12.11	9.22	(0.98)	32.31
Net Profit / (Loss) for the period before tax (after Exceptional and/or Extraordinary items)	12.11	9.22	(0.98)	32.31
Net Profit / (Loss) for the period after tax (after Exceptional and/or Extraordinary items)	9.11	6.86	(0.73)	24.10
Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	8.95	6.27	(0.73)	23.51
Paid-up Equity Share Capital (Face Value of Rs.10/- each)	4.70	4.70	4.70	4.70
Reserves (Other Equity)				73.47
Earnings Per Share (for continuing and discontinued operations) (Face Value of Rs. 10/- each):				
(a) Basic	19.38	14.60	(1.56)	51.29
(b) Diluted	19.38	14.60	(1.56)	51.29
	(not Annualised)	(not Annualised)	(not Annualised)	(Annualised)

Notes:

1) The above is an extract of the detailed format of Quarterly Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Unaudited Financial Results is available on the Stock Exchange website (www.bseindia.com) and on the Company's website (www.dragarwal.com)

2) The Company's operations for the quarter ended 30 June 2021 was impacted on account of the outbreak of COVID-19 pandemic. The results for the quarter are, therefore, not comparable with the corresponding previous periods.

Place: Chennai
Date : 04 August 2022



By order of the Board

Dr. Amar Agarwal
Chairman & Managing Director
DIN No. 00435684